SCHEMBL12436718

SCHEMBL12436718

CC(=O)C1CCC(NC(=O)C(C)(C)C)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.50
EPHX2 P34913 3/20 0.41
PKM P14618 1/20 0.41
PDK1 Q15118 1/20 0.41
PDK2 Q15119 1/20 0.41
PDK3 Q15120 1/20 0.41
PDK4 Q16654 1/20 0.41
LMNA P02545 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
EPHX1 P07099 1/20 0.38
GAA P10253 1/20 0.38
CCR2 P41597 1/20 0.37
SIGMAR1 Q99720 1/20 0.36
POLB P06746 2/20 0.35
HTT P42858 1/20 0.35
CKS1B P61024 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18212333 1.00 ALDH1A1 (0.50) ALDH1A1EPHX2PKMPDK1PDK2
SCHEMBL22722014 1.00 ALDH1A1 (0.50) ALDH1A1EPHX2PKMPDK1PDK2
SCHEMBL4087474 0.87 ALDH1A1 (0.60) ALDH1A1EPHX2PKMPDK1PDK2
SCHEMBL21100016 0.87 ALDH1A1 (0.60) ALDH1A1EPHX2PKMPDK1PDK2
SCHEMBL13446730 0.86 PDK1 (0.43) ALDH1A1EPHX2PKMPDK1PDK2
SCHEMBL12436660 0.86 PDK1 (0.43) ALDH1A1EPHX2PKMPDK1PDK2
SCHEMBL23759977 0.84 ALDH1A1 (0.50) ALDH1A1EPHX2PKMPDK1PDK2
SCHEMBL16886273 0.84 ALDH1A1 (0.50) ALDH1A1PKMPDK1PDK2PDK3
SCHEMBL16886275 0.84 ALDH1A1 (0.50) ALDH1A1PKMPDK1PDK2PDK3
SCHEMBL23760059 0.84 ALDH1A1 (0.50) ALDH1A1EPHX2PKMPDK1PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49686-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-10 US disclosed
US-RE49686-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-10 US disclosed
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-07-21 US disclosed
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME NTSR2, BDKRB1, AVPR1B ALDH1A1 3648/4885EPHX2 1713/4885PKM 1856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.